Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Total 13F shares
-
8,008,863
-
Share change
-
+382,135
-
Total reported value
-
$102,590,269
-
Price per share
-
$12.81
-
Number of holders
-
39
-
Value change
-
+$4,468,806
-
Number of buys
-
17
-
Number of sells
-
16
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q1 2017
As of 31 Mar 2017,
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,008,863 shares.
The largest 10 holders included
FMR LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Pharmstandard International S.A., Cormorant Asset Management, LLC, RA CAPITAL MANAGEMENT, LLC, Foresite Capital Management III, LLC, BlackRock Inc., VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, and STATE STREET CORP.
This page lists
39
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.